Dianthus Therapeutics (NASDAQ:DNTH) CEO Sells 122,918 Shares

13 Mar 2026, 22:18 by Renee Jackson · The Cerbat Gem

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) CEO Marino Garcia sold 122,918 shares of the firm’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Dianthus Therapeutics Stock Down 3.1%

Shares of NASDAQ DNTH traded down $2.46 during trading on Friday, reaching $77.86. 2,278,752 shares of the stock were exchanged, compared to its average volume of 1,180,013. Dianthus Therapeutics, Inc. has a twelve month low of $13.36 and a twelve month high of $88.02. The company has a market capitalization of $3.46 billion, a price-to-earnings ratio of -18.99 and a beta of 1.56. The business’s 50-day moving average price is $52.53 and its 200 day moving average price is $42.56.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last issued its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on DNTH shares. Truist Financial increased their target price on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a report on Monday. Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the company a “buy” rating in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Stifel Nicolaus set a $120.00 price target on Dianthus Therapeutics in a research note on Monday. Finally, HC Wainwright boosted their target price on Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $115.33.

Get Our Latest Analysis on Dianthus Therapeutics

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust grew its position in Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after acquiring an additional 540 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at $40,000. Raymond James Financial Inc. bought a new stake in Dianthus Therapeutics in the second quarter worth $27,000. Russell Investments Group Ltd. acquired a new position in Dianthus Therapeutics during the third quarter worth $64,000. Finally, Royal Bank of Canada lifted its position in shares of Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after buying an additional 542 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics News Roundup

Here are the key news stories impacting Dianthus Therapeutics this week:

Positive Sentiment: Company news: management announced an early Phase‑3 “go” decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters’ option), strengthening the company’s cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering…
Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics (NASDAQ:DNTH) Raised to “Strong-Buy” at Raymond James Financial
Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase Following Analyst Upgrade
Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.

About Dianthus Therapeutics

(Get Free Report)